Pharmacy vs. Diversion: Technology, Education Key

January 42017Pharmacy vs. Diversion: Technology, Education Key

Drug Diversion is a risk for all provider types and drug vendors. Whether you are a Retail Pharmacy, Grocery Chain, Distributor, or Health System, controls and close monitoring must be put in place to prevent the misuse and theft of drugs.

Read More

Incoming Congress immediately will pick up Obamacare repeal

December 272016Incoming Congress Immediately Will Pick up Obamacare Repeal

While Republicans vow to address the repeal of the ACA immediately, as to avoid costly delays, the Trump administration has a significant amount of work ahead of them in 2017.

Read More

The Alinea Group Announces Corporate Partnership with 340B Health

November 302016The Alinea Group Announces Corporate Partnership with 340B Health

The Alinea Group, LLC is excited to announce its Corporate Partnership with 340B Health, the nation’s leading advocate and resource for the safety-net providers across the nation. 340B Health Partnership gives 340B Health 1,000+ Members increased access to Alinea’s Pharmacy Enterprise Solutions group.

Read More

Models that Work: Managed Medicaid and 340B Covered Entities Partner to Prevent Duplicate Discounts in Oregon

November 292016Models that Work: Managed Medicaid and 340B Covered Entities Partner to Prevent Duplicate Discounts in Oregon

Through a standardized process, utilizing entity identification codes and EDI, Oregon MCO’s will now be able to accurately identify 340B eligible claims.

Read More

HRSA Proposed Rule: Administrative Dispute Resolution (ADR)

September 82016HRSA Proposed Rule: Administrative Dispute Resolution (ADR) Comments Due Oct. 11th, 2016

Under a HRSA proposed rule that would implement the Affordable Care Act requirement that a binding administrative dispute resolution (ADR) process for the 340B program be instituted, providers can file challenges if they believe they were overcharged for drugs purchased through the program. The proposed process also would be available to drug manufacturers.

Read More

340B Health's Comment on Transmission of Mega-Guidance

September 22016340B Health's Comment on Transmission of Mega-Guidance to OMB for Final Review

HRSA sent its proposed 340B Omnibus Guidance to the White House OMB for review on August 1, 2016. According to reports based on an entry on the OMB Website, it is believed that HRSA has subsequently submitted the final guidance on September 1, 2016.

Read More

Ever-Escalating Cost of Cancer Drugs

June 22016The Ever-Escalating Cost of Cancer Drugs

The total cost of oncology drugs and supportive care medications surged 11.5 percent in 2015 to reach $107 billion globally, according to a new study from IMS Institute for Healthcare Informatics.

Read More

Safety Advocates 'Horrified' by UW Medical Center Investigation Results

May 122016Safety Advocates 'Horrified' by UW Medical Center Investigation Results

A teaching hospital in Seattle was recently cited for negligence in maintaining sterile drug mixing and compounding areas for a period of 17 months, including in appropriate handling and identification of expired medications.

Read More

How Theft Ring Stole Millions of Drugs From Emory

March 102016How Theft Ring Stole Millions of Drugs From Emory

Emory University Hospital Midtown faces sanctions after investigators uncovered a criminal scheme in which employees used its pharmacy to order more than a million doses of addictive prescription drugs for illegal use.

Read More

CMS Issues Final Rule with Comment Period Addressing Medicaid Drug Reimbursement and Rebates

February 232016The Wait Is Over: CMS Issues Final Rule with Comment Period Addressing Medicaid Drug Reimbursement and Rebates

The final AMP rule will require that states pay for 340B drugs billed to fee-for-service Medicaid at actual acquisition cost or the 340B ceiling price plus a professional dispensing fee, require that states establish ways for covered entities to identify 340B drugs used for Medicaid managed ...

Read More

Bipartisan Budget Act Section 603's Impact on Off-campus Hospital Departments

February 152016Bipartisan Budget Act Section 603's Impact on Off Campus Hospital Departments

340B covered entities, in the process of or considering acquisition and/or development of new off-campus outpatient locations, should evaluate the impact of the Medicare payment changes in Section 603 for “site-neutral” locations.

Read More

Amgen Providing 340B Refunds on Most of Its Products. Price restatements include Enbrel, Neulasta, and Prolia

February 122016Amgen Providing 340B Refunds on Most of its Products. Price Restatements Include Enbrel, Neulasta, and Prolia

Amgen is providing 340B covered entities refunds. The refunds are related to pricing inaccuracies and will include its most popular and expensive products Enbrel, Neulasta, and Prolia.

Read More

MedPAC's proposed cut to hospitals in 340B drug program hits Congress in March

February 112016MedPAC's Proposed Cut to Hospitals in 340B Drug Program Hits Congress in March

Medicare Part B cuts may be imminent. 340B covered entities need to understand the potential financial impact of reimbursement reduction, and identify ways to mitigate revenue-loss and offset losses.

Read More

The Alinea Group Announces Corporate Partnership With 340B Health

February 102015The Alinea Group Announces Corporate Partnership With 340B Health

340B Health Partnership gives 340B Health 1,000+ Members increased access to Alinea’s Pharmacy Enterprise Solutions group.

Read More

HRSA Aims to Issue Final 340B Mega-guidance by Late Summer

December 032015HRSA Aims to Issue Final 340B Mega-Guidance by Late Summer

With the formal comment period for Omnibus Guidance (“Mega Guidance”) now complete, and HRSA has released a statement that the final guidance is expected to be published in September 2016. A key component to the changes, 340B covered entities need to be ready to meet the ...

Read More

340B Orphan Drug Exclusion Upheld

October 152015340B Orphan Drug Exclusion Upheld

This ruling means that rural referral centers, sole community hospitals, critical access hospitals and cancer hospitals will no longer be able to purchase orphan drugs at 340B pricing for any condition. The ruling does not affect ...

Read More

Review Of Proposed 340B Omnibus Guidance: How We Got Here And What It Says

September 52015Review of Proposed 340B Omnibus Guidance: How We Got Here and What it Says

Amid pressures to provide increased oversight for the 340B program, HRSA releases Omnibus Guidance, termed ‘Mega-Guidance,’ to provide clarification of 340B program requirements for covered entities and manufacturers

Read More